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Background. Despite improved diagnostics, pulmonary pathogens in immunocompromised children frequently evade detec-
tion, leading to significant mortality. Therefore, we aimed to develop a highly sensitive metagenomic next-generation sequencing 
(mNGS) assay capable of evaluating the pulmonary microbiome and identifying diverse pathogens in the lungs of immunocompro-
mised children.
Methods. We collected 41 lower respiratory specimens from 34 immunocompromised children undergoing evaluation for 
pulmonary disease at 3 children’s hospitals from 2014–2016. Samples underwent mechanical homogenization, parallel RNA/DNA 
extraction, and metagenomic sequencing. Sequencing reads were aligned to the National Center for Biotechnology Information 
nucleotide reference database to determine taxonomic identities. Statistical outliers were determined based on abundance within 
each sample and relative to other samples in the cohort.
Results. We identified a rich cross-domain pulmonary microbiome that contained bacteria, fungi, RNA viruses, and DNA 
viruses in each patient. Potentially pathogenic bacteria were ubiquitous among samples but could be distinguished as possible causes 
of disease by parsing for outlier organisms. Samples with bacterial outliers had significantly depressed alpha-diversity (median, 0.61; 
interquartile range [IQR], 0.33–0.72 vs median, 0.96; IQR, 0.94–0.96; P < .001). Potential pathogens were detected in half of samples 
previously negative by clinical diagnostics, demonstrating increased sensitivity for missed pulmonary pathogens (P < .001).
Conclusions. An optimized mNGS assay for pulmonary microbes demonstrates significant inoculation of the lower airways of 
immunocompromised children with diverse bacteria, fungi, and viruses. Potential pathogens can be identified based on absolute 
and relative abundance. Ongoing investigation is needed to determine the pathogenic significance of outlier microbes in the lungs of 
immunocompromised children with pulmonary disease.
Keywords. intensive care units, pediatric; immunocompromised host; metagenomics; respiratory tract infections; microbiota.
Last year in the United States, approximately 15 000 children 
were diagnosed with cancer, 2000 underwent solid organ trans-
plantation, and 2500 underwent hematopoietic cell transplan-
tation (HCT) for an increasingly broad set of life-threatening 
diseases [1–3]. Despite improved safety of antineoplastic and 
transplantation-based therapies, the risk of infectious complica-
tions such as pneumonia remains high [4, 5]. Due to the inhib-
itory effect of antimicrobial pretreatment on culture growth, 
impaired serologic immunity, and the limited preselected 
targets of multiplex assays, current microbiologic diagnostics 
frequently fail to identify pathogenic organisms [6]. The signif-
icant mortality associated with undiagnosed pulmonary infec-
tions is evident in postmortem case series of pediatric HCT 
patients, in whom previously undetected pulmonary pathogens 
have been identified in 30%–50% [7].
Unlike assays that target the 16S and/or 28S/ITS ribosomal 
RNA amplicons, unbiased metagenomic next-generation 
sequencing (mNGS) can detect bacteria, viruses, and fungi and 
has shown promising results for diagnosing neurologic and 
ocular infections [8–10]. However, the identification of fila-
mentous molds such as Aspergillus spp. remains difficult due to 
thick extracellular matrices and the relatively small inoculum 
required to induce disease [11–14]. Unfortunately, off-the-shelf 
assays for respiratory biospecimens have proven inadequate to 
survey the variety of organisms present in thick and mucoid 
respiratory secretions. As such, unlike the better-characterized 
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microbiomes of the human gastrointestinal tract and naso-
pharynx, data describing the composition of the pulmonary 
microbiome are sparse and insufficient to reliably discriminate 
between health and disease [15].
Therefore, we conducted a pilot study aimed to develop a 
highly sensitive mNGS assay capable of detecting myriad pul-
monary bacterial, fungal, and viral pathogens and to test that 
assay on a retrospective cohort of immunocompromised chil-
dren who underwent lower respiratory tract sampling as evalu-
ation for suspected pulmonary infection. We hypothesized that 
an optimized mNGS assay could improve characterization of 
the pulmonary microbiome and identify potential pulmonary 
pathogens in this high-risk population.
METHODS
Development of Optimized mNGS Assay
We created mock-positive bronchoalveolar lavages (BALs) by 
spiking Aspergillus niger broth into aliquots of BAL containing 
known Haemophilus influenzae/Human Adenovirus B coinfec-
tion (Supplementary Material 1). An Aspergillus species was 
chosen as an optimization benchmark given its thick polysac-
charide cell wall and extreme clinical importance of invasive 
mold in this patient population [16].
Sample Preparation
We tested nucleic acid extraction conditions by combining 200 μL 
of mock-positive BAL with either 600 μL DirectZol, 600 μL lysis 
buffer, or 200 μL DNA/RNA Shield (Zymo), followed by mechan-
ical homogenization with either 0.1 mm or 0.5 mm glass bashing 
beads (Omni) for 2, 5, or 8 cycles of 25 seconds, bashing at 30 Hz 
with 60 seconds rest on ice between each cycle (TissuerLyser II, 
Qiagen). Samples homogenized in DNA/RNA shield also under-
went enzymatic mycolysis with either 0.15 mg or 0.38 mg protein-
ase K at 23°C for 30 or 60 minutes (Zymo) or with 0.4 mg, 1.2 mg, 
4 mg, or 8 mg Yatalase (Takara Bio Inc.) at 23°C or 37°C for 60 
or 90 minutes. Subsequently, all samples underwent 10 minutes 
of centrifugation at 4°C, and the supernatant was used for paral-
lel DNA/RNA extraction (Zymo ZR-Duet DNA/RNA MiniPrep 
Kit). Aspergillus niger nucleic acid yield was measured using an 
orthogonal digital droplet polymerase chain reaction (PCR) 
assay with pan-Aspergillus primers (Supplementary Material 2) 
[17]. RNA and DNA sequencing libraries were prepared in par-
allel (New England Biolabs NEBNext Ultra-II Library Prep) and 
underwent 125 nucleotide paired-end sequencing on an Illumina 
HiSeq 4000 instrument (Supplementary Material 3).
Bioinformatics Pipeline
Resultant.fastq files were processed using a previously described 
pipeline that consisted of several open-source components [8, 9]. 
Briefly, reads underwent iterative removal of host (Hg38/PanTro), 
low-quality, low-complexity (Lempel–Ziv–Welch [LZW] compres-
sion ratio >0.45), and redundant sequences using STAR, Bowtie2, 
PriceSeqFilter, and CD-HIT-DUP [18–21]. The remaining 
sequences were aligned to the National Center for Biotechnology 
Information (NCBI) nonredundant nucleotide database using 
GSNAPL for assignment of taxonomic IDs [22]. Microbes were 
described as potentially pathogenic or typically nonpathogenic 
based on a priori literature review (Supplementary Material 4).
Controls
To assess microbial contaminants in our reagents and labora-
tory environment, we sequenced 8 control samples containing 
spiked-in HeLa RNA (Supplementary Material 5).
Analysis
The prevalence of each microbe in each respiratory sample was 
described using 2 criteria: abundance relative to other microbes in 
the same sample, wherein we normalized sequencing reads per mil-
lion total sequencing reads (rpm), and (2) abundance relative to the 
same microbe in other samples in the cohort, wherein we normal-
ized sequencing reads as the number of standard deviations above or 
below the mean log10-transformed rpm for the total cohort (Z-score). 
Given the anticipated wide array of respiratory bacteria and the pau-
city of knowledge regarding the significance of low-level viruses and 
fungi, we aimed to maximize specificity for bacterial pathogens and 
to maximize sensitivity for viral and fungal pathogens [15, 23, 24]. 
Therefore, we defined microbial outliers as those with Z-score ≥2 and 
≥10 rpm (bacteria) or ≥1 rpm (viruses/fungi). The Simpson diversity 
index was used to associate the loss of bacterial diversity with the pres-
ence of outlier microbes (Supplementary Material 6) [25].
Validation
Respiratory samples with outlier pathogens that were not iden-
tified on clinical testing were sent to reference laboratories for 
orthogonal confirmatory testing (Supplementary Material 7).
Patients
To test the optimized mNGS assay, we prospectively screened 
and approached immunocompromised patients age ≤25 years 
undergoing clinically indicated lower respiratory sampling 
between September 2014 and April 2016 at the University of 
California San Francisco Benioff Children’s Hospital, Indiana 
University Riley Hospital for Children, and the University of 
Minnesota Masonic Children’s Hospital. Patients were enrolled 
with consent. After respiratory samples were collected for clin-
ical purposes, excess volume was separated, placed on dry ice 
within 10 minutes of the original procedure, and banked at 
−70°C until processing (Supplementary Material 8). This study 
was approved by each site’s institutional review board.
RESULTS
Development of Optimized mNGS Assay
Iterative optimizations demonstrated that mechanical homog-
enization of BAL using 0.5-mm glass bashing beads for 5 cycles 
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in DNA/RNA shield without mycolytic enzymes yielded the 
highest quantity of A. niger nucleic acid (Supplementary Material 
9, Supplementary Figure  1a–1d). This extraction protocol per-
formed similarly when applied to clinical isolates of A. fumigatus 
(Supplementary Figure 1e). When sequencing RNA to a depth of 
25 million reads per 200 μL BAL, this protocol improved the lower 
limit of detection (LLOD) of A. niger by approximately 100-fold 
(59.60 colony-forming units [CFU] preoptimization; 95% confi-
dence interval [CI], 37.70–95.36 vs 0.42 CFU postoptimization; 
95% CI, 0.12–1.40; paired T test P < .001; Supplementary Figure 2). 
However, sequencing simultaneously extracted DNA to the same 
depth yielded a 10-fold inferior A. niger LLOD (6.13 CFU; 95% CI, 
4.16–9.04; paired T test P < .001; Figure 1). The optimization did 
not change the detection of H. influenzae or Human Adenovirus B 
(T test P = .343 and P = .420, respectively).
Application of mNGS Assay
Using the optimized protocol described above, we conducted 
mNGS on 41 clinical samples obtained from 34 patients 
(Table  1). Sequencing results are summarized below, with 
sequencing quality reported in Supplementary Tables  1 and 
2, raw sequencing files available in NCBI dbGaP (https://
www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_
id=phs001684.v1.p1), and detailed patient results in Appendix 
1. Negative controls demonstrated minimal environmental con-
tamination (<1 rpm of pathogenic bacteria and no pathogenic 
fungi or viruses Supplementary Table 3).
Bacteria
The vast majority of taxa derived from bacterial alignments 
were present at low abundance and in quantities similar across 
all samples in the cohort. Specifically, 81.7% of bacterial gen-
era were identified at <10 rpm and within 2 standard deviations 
of the cohort mean (Z-score  <  2; Figure  2A). These included 
potentially pathogenic bacterial genera such as Escherichia, 
Klebsiella, Pseudomonas, Staphylococcus, Stenotrophomonas, and 
Streptococcus, which were identified in nearly all samples at lev-
els well above those detected in the negative controls (38, 39, 40, 
38, 41, and 40 of 41 samples, respectively). Conversely, only 0.4% 
of detected bacterial genera met outlier criteria. These outliers 
included 10 potentially pathogenic bacteria identified in 13/41 
patient samples (Corynebacterium, Enterobacter, Enterococcus, 
Escherichia, Haemophilus, Klebsiella, Mycoplasma, Pseudomonas, 
Staphylococcus, and Streptococcus). Samples with outlier bacte-
rial pathogens had significantly depressed alpha-diversity of the 
bacterial microbiome (median, 0.61; interquartile range [IQR], 
0.33–0.72 vs 0.96; IQR, 0.94–0.96; P < .001; Figure 3).
Fungi
Relative to bacterial alignments, fungal alignments were sig-
nificantly less prevalent in the cohort. Further, 92.1% of fun-
gal genera were quantified below 1 rpm (Figure 2B). Evidence 
supporting these alignments is limited by the rarity of the 
reads themselves. Only 3.4% of fungal genera met outlier cri-
teria; these included potentially pathogenic fungi identified 
in 7/41 patient samples (Alternaria, Aspergillus, Candida, 
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Figure 1. Aspergillus niger lower limit of detection by optimized next-generation sequencing. At the lower limit of detection (LLOD) of RNA sequencing (RNAseq), the 
optimized assay was able to detect as few as 0.42 Aspergillus niger colony-forming units (CFU; 95% confidence interval [CI], 0.12–1.40), whereas at the LLOD of DNAseq, 
the optimized assay was able to detect as few as 6.13 A. niger CFU (95% CI, 4.16–9.04; paired T test P < .001). Red data represent RNAseq and blue data represent DNAseq. 
Dotted lines represent the 95% CIs for each linear regression. (Insert) Parallel detection of A. niger RNA using digital droplet polymerase chain reaction assay. As nucleic 
acid bioavailability may vary across Aspergillus species, these results may not be directly extrapolated to other Aspergillus species and other medically relevant molds. 
Abbreviations: BAL, bronchoalveolar lavage; CFU, colony-forming unit; ddPCR, droplet digital polymerase chain reaction; seq, sequencing.
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Cladosporium, Cryptococcus, Fusarium, and Pneumocystis). 
While Aspergillus RNA levels were detectable in 14/41 patient 
samples, only 1 was positive for invasive pulmonary aspergillo-
sis (IPA) by both culture and galactomannan assay (Figure 2B, 
labeled). Although the remaining 13 were all culture negative, 
12/13 had received fungicidal or fungistatic anti-Aspergillus 
pharmacotherapy within 48 hours of sample collection, sug-
gesting that empiric antifungal pharmacotherapy significantly 
confounds the association between Aspergillus RNA and growth 
in culture. Aspergillus RNA levels did not correlate with growth 
in culture (T test P = .148) but demonstrated weak association 
with BAL galactomannan (P < .001; Supplementary Figure 3).
Viruses
In contrast with bacteria and fungi, a significantly larger por-
tion of RNA alignments to viral genera were present at high 
abundance, and 30.5% met outlier criteria (Figure 2C and 2D). 
Communicable respiratory viruses with abundant alignments 
were identified in approximately one third of all patient sam-
ples (13/41) and included Adenoviruses A and C, Bocavirus, 
Coronaviruses 229E and OC43, Influenzaviruses A and C, 
Parainfluenzavirus 3, and Rhinoviruses A and C. Although 4 
Rhinoviruses met outlier criteria, an additional 3 Rhinoviruses 
were abundant but had Z-scores between +0.92 and +1.78. 
Additionally, 2 patients had viral coinfections (Parainfluenza-3 
and Influenza-C; Adenovirus-C and Rhinovirus-A). Although 
there were no cases of clinically suspected herpesvirus pneumo-
nitis, Epstein-Barr virus, Cytomegalovirus, HHV-6, and HHV-7 
were identified in low abundance in 9/41 samples. Viral gen-
era of uncertain or unlikely pathogenicity were also identified 
in 21/41 samples and included Papillomaviruses, WU and KI 
Polyomaviruses, and Torquetenoviruses (2, 5, and 18 samples, 
respectively).
Comparison to Clinical Testing
Clinical testing identified causative pathogens in 41.4% of sam-
ples (n = 17; Figure 4). Of these, 11 were concordantly identified 
as outliers by mNGS, and 3 of these 11 contained outlier quan-
tities of RNA aligning to a second previously undetected poten-
tial copathogen (Bocavirus, Corynebacterium, and Influenza-C). 
An additional 3 were identified by mNGS but were not classi-
fied as outliers (2 cases of Aspergillus diagnosed by galactoman-
nan and 1 case of Rhinovirus-A), and another 3 had a different 
outlier pathogen identified by mNGS (Coronavirus 229E twice 
and Coronavirus OC43 once). Clinical testing did not identify 
any pathogens in 58.5% of samples (n = 24). Here, mNGS was 
able to identify statistically outlying potential pathogens in 
11/24 cases, including a variety of bacteria (ie, P.  aeruginosa, 
E. cloacae, M. pneumoniae), fungi (ie, C. glabrata), and viruses 
(ie, Rhinovirus-A).
Orthogonal Validation
Statistical approaches to separate commensals from pathogens 
are inherently imperfect; therefore, we undertook orthogonal 
validation as an independent means to verify these results. 
Organisms detected by mNGS but not clinical testing were 
validated with commercially available Clinical Laboratory 
Improvement Amendments (CLIA)-approved assays performed 
Table 1. Characteristics of Enrolled Patients
Demographics (n = 34 patients) Descriptor
Age (median years, IQR)a 11.2 (IQR, 4.3–16.2)
Sex
 Female 16 (47%)
 Male 18 (53%)
Race
 White 26 (76%)
 Black  1 (3%)
 Asian  1 (3%)
 Hawaiian/Pacific Islander  1 (3%)
 Other  1 (3%)
 Unknown  4 (12%)
Ethnicity
 Hispanic/Latino  9 (26%)
 Not Hispanic/Latino 24 (74%)
Primary medical condition
 Allogeneic HCTb 20 (59%)
 Autologous HCT  3 (9%)
 Acute leukemia (without HCT)  2 (6%)
 Primary immunodeficiency (without HCT)  4 (12%)
 Severe aplastic anemia (without HCT)  2 (6%)
 Solid tumor (without HCT)  1 (3%)
 Solid organ transplantation  2 (6%)
Clinical course (n = 41 episodes)
 Lower respiratory sample type
  BAL 33 (80%)
  Mini-BAL  4 (10%)
  ETT aspirate  4 (10%)
 Therapies (median number of therapies, IQR)
  Antibacterials  4 (1–5)
  Antivirals  1 (0–2)
  Antifungals  1 (0–2)
  Immunomodulation  2 (0–2)
 Patients with identified pathogen
  Any pathogen 13 (32%)
  Bacteria only  5 (12%)
  Fungi only  1 (2%)
  Viruses only  4 (10%)
  Multiple pathogens  3 (7%)
 Outcomes
  Required pediatric intensive care unit admission 21 (51%)
  Required >24 hours mechanical ventilation 17 (41%)
  Hospital deathc 10 (29%)
Abbreviations: BAL, bronchoalveolar lavage; ETT, endotracheal tube; HCT, hematopoietic 
cell transplantation; IQR, interquartile range.
aAge at first specimen collection. 
bIndications for allogeneic HCT were acute leukemia (12/20), primary immunodeficiency 
(3/17), severe aplastic anemia (2/17), myeloproliferative/myelodysplastic disorder (2/17), 
and osteopetrosis (1/17). 
cHospital death n = 10/34 (29%).
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on aliquots of the original unprocessed sample (Supplementary 
Material 7). All validation tests were concordant with mNGS 
with 1 exception: 28S/ITS amplicon DNA sequencing failed to 
identify C. glabrata in sample 37. For this sample, we confirmed 
the presence of this organism with 3 separate species-specific 
reverse-transcription primer sets followed by Sanger sequenc-
ing. These data demonstrate that mNGS has significantly 
greater sensitivity for detecting potential pulmonary pathogens 
than current clinical diagnostics (McNemar’s P < .001).
DISCUSSION
In this study, we developed and optimized an mNGS assay 
with adequate sensitivity to identify bacteria, fungi, and both 
RNA and DNA viruses within the lower respiratory tract of 
immunocompromised children. In doing so, we identified a 
rich molecular portrait of the pulmonary microbiome in this 
vulnerable population. Further, by comparing the quantity of 
microbial nucleic acid to that of other microbes within a sample 
and to other samples within the cohort, we were able to identify 
outlying potential pathogens in approximately half of clinically 
negative samples.
Due to inherent challenges in sampling the lower respiratory 
tract, the pulmonary microbiome was not one of the original 
sites studied in the 2008 Human Microbiome Project, and 
its exploration has lagged decades behind similar analyses of 
human intestinal, cutaneous, and nasopharyngeal microbiomes 
[26]. In addition, studies of the pulmonary microbiome in chil-
dren necessarily lack healthy matched controls due to the inher-
ent risks of anesthesia and bronchoscopy [27]. In this study, 
we found that many potentially pathogenic bacteria such as 
Pseudomonas and Streptococcus are ubiquitous, and hence their 
abundance needs to be contextualized by cohort-specific norms. 
For example, 100% of samples had detectable Pseudomonas 
RNA, but only sample 29 had Pseudomonas RNA detected more 
than 2 standard deviations above the cohort mean. Normalizing 
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Figure  2. Microbial alignments detected in the lungs of immunocompromised children. Red dots represent potentially pathogenic microbes that are both abundant 
(≥10 rpm for bacteria or ≥1 rpm for fungi or viruses) and identified at levels greater than most other samples in the cohort (Z-score ≥2). Hollow red dots indicating Bocavirus 
and Pneumocystis are used to indicate organisms observed only once in this cohort. Blue dots represent all other potentially pathogenic microbes; light blue dots represent 
typically nonpathogenic microbes. Subplots show (A) all bacteria, (B) fungi, (C) RNA viruses, and (D) DNA viruses identified across all samples in the cohort. For the purpose 
of the Z-score calculation, the value of log10-transformed reads for undetected microbes was assumed to equal –2, just below the lower limit of detection for our sequencing 
depth (log10[0.01rpm] = –2). Abbreviation: seq, sequencing.
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population-dependent measurements is common in pediatrics 
and appears well suited to describe aspects of the pulmonary 
microbiome [28–30].
To date, the majority of metagenomic sequencing assays have 
targeted amplicons within the 16S or 28S rRNA subunits, allow-
ing detection of pulmonary bacteria or fungi, but not both, and 
not viruses [31]. Recently, unbiased mNGS assays have allowed 
detection of both bacterial and viral nucleic acid but have 
lacked ideal sensitivity for detecting filamentous mold [11, 12]. 
Although the European Aspergillus PCR Initiative has described 
ideal methodology for extracting fungal nucleic acid from blood, 
the optimal extraction conditions for respiratory specimens 
remain less well defined [32, 33]. This study confirms the need 
for aggressive mechanical homogenization in stabilizing media 
in order to detect molds such as Aspergillus while simultaneously 
preserving the detection of bacteria and viruses [34–36]. As the 
majority of commercial sequencing assays measure DNA, this 
study adds to the literature by demonstrating that RNA sequenc-
ing is >10 times more sensitive for the detection of such fastidious 
organisms, which we speculate may be due to high copy numbers 
of particular RNA templates present in active organisms [37].
Using optimized mechanical homogenization, Aspergillus 
RNA was detected in 34.1% of samples and no negative con-
trols, suggesting that the lungs of immunocompromised chil-
dren are frequently exposed to low levels of potentially viable 
Aspergillus organisms. These data are novel in the pediatric 
population and are congruous with surveillance data from 
neutropenic and nonneutropenic adults [38, 39]. However, 
as only 10% of samples originated from patients with sus-
pected IPA, patient-specific factors such as antifungal pre-
treatment, immune reconstitution, alloreactive inflammation, 
and impaired mucociliary clearance remain crucial in deter-
mining which child might develop IPA [16]. While this study 
was not powered to assess performance characteristics of this 
assay for IPA, pan-fungal and Aspergillus-specific PCR have 
demonstrated 76%–79% sensitivity and 93%–95% specificity 
for probable/proven IPA [14, 40–47]. Combining nucleic acid 
tests with galactomannan can hasten diagnosis and improve 
Figure 4. Comparison of clinical laboratory results vs metagenomic next-generation sequencing (mNGS) results. Clinical laboratory results were determined by review of 
medical charts. n = 17 patients had samples with a pathogen detected clinically, as determined by interpretation of clinical microbiologic testing by the treating physician. Of 
these, n = 11 had concordant pathogens of outlier quantities on mNGS (Adenovirus/Rhinovirus, Aspergillus fumigatus, Enterobacter cloacae, Escherichia coli, Haemophilus 
influenzae, Haemophilus influenzae/Parainfluenza virus, Mycoplasma pneumoniae [n = 2], Pneumocystis jirovecii/Rhinovirus-A, Rhinovirus-C, and Staphylococcus aureus); n = 
3 had concordant pathogens identified on mNGS but not in outlier quantities (Aspergillus [n = 2] and Rhinovirus-A); and n = 3 had an alternative pathogen identified on mNGS 
(Human coronavirus 229E [n = 2] and Human coronavirus OC43). n = 24 patients had samples without a pathogen detected clinically. Of these, n = 11 had a potential pathogen 
present in outlier quantities on mNGS (Candida glabrata, Cytomegalovirus, Cryptococcus [n = 2], Enterobacter cloacae, Human herpesvirus-6, Mycoplasma pneumoniae, 
Rhinovirus-A, Pseudomonas aeruginosa/Influenza-A, Staphylococcus epidermidis, and Streptococcus pneumoniae) and n = 13 did not. Abbreviation: mNGS, metagenomic 
next-generation sequencing.
** P < .001
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Figure 3. Respiratory samples with outlier pathogens have depressed bacterial 
alpha-diversity. Diversity of the bacterial microbiome was significantly decreased in 
samples with potentially pathogenic bacteria present at ≥10 rpm of the pulmonary 
bacterial microbiome and Z-score ≥2 (median, 0.61; interquartile range [IQR], 0.33–
0.72; n = 13 vs median, 0.96; IQR, 0.94–0.96; n = 28; P < .001). Simpson diversity 
index cutoffs of ≥0.8 or ≥0.9 showed 90.3% (95% confidence interval, 77.6–96.2) 
and 100% negative predictive value for the presence of an outlier bacterial patho-
gen, suggesting that the identification of bacterial dysbiosis may be a useful screen 
for recognizing possible bacterial infections.
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clinical outcomes in some populations [48–51]; further, incor-
poration of immune function may also improve discrimination 
of colonization and invasive mycosis [52–56]. Importantly, for 
all nucleic acid–based tests, measurable Aspergillus yield varies 
among species and according to life stage, cell wall character-
istics, and hydrophobicity [57]. Therefore, any future clinical 
mNGS assay will need to be benchmarked against numerous 
Aspergillus species as well as other medically relevant fungi in 
order to have the broadest utility.
Consistent with emerging data in pediatrics, we also detected 
herpesviruses such as CMV and HHV-6 in low abundance among 
many children in the cohort [58, 59]. Interestingly, a number of 
typically nonpathogenic viruses such as Torquetenovirus and 
KI Polyomavirus were present in more than half of the cohort. 
While data supporting the direct pathogenicity of these viruses 
are lacking, they may indicate immune dysfunction and pre-
dict numerous post-transplant infectious and alloimmune 
complications [60–62]. Future studies aimed at characterizing 
longitudinal changes in the pulmonary virome of immunocom-
promised children are warranted.
By characterizing the distribution of pulmonary microbes 
within the cohort, we identified statistically outlying potential 
pathogens in half of clinically negative samples. Most newly 
detected cultivable organisms were isolated from patients 
who had been pretreated with antimicrobials, highlighting 
the importance of culture-independent techniques [15]. In 
addition, several newly detected viruses were not included in 
clinical multiplex PCR assays (Human coronavirus, Human 
Bocavirus, Influenzavirus-C) [63]. While this study suggests 
that many idiopathic pulmonary complications may be associ-
ated with infections, one quarter of samples were concordantly 
negative for pathogens on clinical and mNGS testing, empha-
sizing the ongoing significance of noninfectious pulmonary 
complications in this population. Future clinical validation of 
mNGS may demonstrate utility in safely excluding infections 
and allowing amplified immunomodulation in patients with 
predominantly inflammatory pulmonary syndromes [64].
Our study has several strengths. First, we optimized the 
extraction of Aspergillus spp. RNA while preserving detection 
of bacterial and viral nucleic acid. Second, we proposed a logi-
cal analytical framework that ranks organism abundance both 
within a sample and relative to other samples. Third, outlier 
pathogens identified by mNGS that were not detected clinically 
were subsequently validated by orthogonal assays. Fourth, we 
provide, to our knowledge, the first evaluation of the pulmo-
nary microbiome in immunocompromised children.
Our study has several limitations. First, while the Z-score 
was useful in deemphasizing commonly abundant organisms 
(ie, S. pneumoniae), it may have overvalued uncommon organ-
isms with less abundant transcripts (ie, CMV); additional larger 
studies will naturally strengthen the utility of Z-score analyses. 
Second, because the relationship between microbe quantity and 
sequencing reads varies across organisms based on nucleic acid 
accessibility and the availability of annotated reference genomes, 
future clinical application of an mNGS assay will require vali-
dation on numerous clinically relevant species. Third, samples 
with abundant nucleic acid from human epithelial cells, leuko-
cytes, viruses, and other sources may have reduced detection of 
sparse or fastidious microbes. Finally, as with all mNGS assays, 
the identification of microbial nucleic acid does not directly 
confirm the presence of viable, live organisms; does not directly 
implicate that microbe as a contributor to pulmonary disease; 
and does not exclude less abundant organisms as potential con-
tributors to pulmonary disease. Future studies are needed to 
determine whether prospective use of mNGS in a clinically rel-
evant time frame might affect patient management and improve 
outcomes. In order to optimize patient outcomes, we advocate 
for ongoing multidisciplinary collaboration among clinicians, 
laboratory scientists, and bioinformaticians.
CONCLUSIONS
In summary, we present an optimized mNGS assay that revealed 
a rich bacterial, fungal, and viral pulmonary microbiome in 
immunocompromised children and identified potential patho-
gens in half of clinically negative samples. As such, advanced 
organism detection offers the potential for early implementa-
tion of targeted therapy and the possibility for improved clini-
cal outcomes in immunocompromised children. We invite the 
scientific and clinical community to participate in an ongoing 
multicenter collaborative clinical trial aimed at further refining 
this emerging technology [65].
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